In patients with diabetic kidney disease (DKD), there are several trials confirming the benefit of SGLT2 inhibitors (Table 1), in addition to renin–angiotensin system (RAS) blockade, in decreasing HF events [21,22,23]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.